AINDEX
Markets

OKYO Pharma Limited (OKYO)

OKYONASDAQ-CMBiotechnology: Biological Products (No Diagnostic Substances)

$1.35

0.0000 (0.00%) today

At the close, Nov 13, 4:00 PM ET. Pre-market $1.31 -2.96%

+1.50% 1D
Market cap
$68.75m
P/E
–
EPS, last 4 quarters
–
Dividend yield
–
Day range
–
52-week range
$1.26 to $3.20
Average volume
–
Previous close
$1.35

Analysts

2 covering

Buy2 buy, 0 hold, 0 sell

Targets a year out average $6.00, +344.4% from here

$5.00now $1.35$7.00

Earnings

next estimate $-0.0300

Next report

Financials

No quarterly figures from the source.

News

8 latest

The company

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. Lead candidate, urcosimod for neuropathic corneal pain (NCP), recently announced first patients enrolled in Phase 3 NEPTUNE trial.

Sector
Health Care
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ-CM
Region
Europe

Often looked at with it

Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.